MAIA Biotechnology reports Q1 2023 net loss $4.1M; positive THIO-101 Phase 2 data and $5.75M offering

MAIA Biotechnology, Inc.

2023-Q1 EPS reported -$0.38

Cash $7.6M at March 31, 2023; net loss $4.1M for Q1 2023 vs $3.9M for Q1 2022.
R&D expenses $2.2M, G&A expenses $2.0M for the quarter, both modestly higher YoY.
Completed Part A safety lead-in of THIO-101 Phase 2 trial; first two patients alive ~10 and 9 months post treatment.
THIO showed complete and durable responses in hepatocellular carcinoma in vivo models, potentiated with checkpoint inhibitor.
Raised $5.75M gross from public offering of 2,555,500 shares at $2.25 per share.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAIA Biotechnology, Inc. reported first quarter ended March 31, 2023 results: net income approximately $4.1 million.

Period: first quarter ended March 31, 2023
Net income: approximately $4.1 million
Result: reported results

Exact text from the filing

Net loss was approximately $4.1 million for the quarter ended March 31, 2023, as compared to net loss of approximately $3.9 million for the quarter ended March 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-007055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.